These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 5469312)

  • 41. The problems of drug research and development.
    Lasagna L
    Hosp Formul; 1976 Jan; 11(1):28-9. PubMed ID: 10236458
    [No Abstract]   [Full Text] [Related]  

  • 42. [26th Report on the regular meeting of the Central Expert Committee for the drug trade (ZGA) on March 17, 1966 including the meeting of the governing body on January 27, 1966 as well as the consultation on the health care preparations on February 23, 1966].
    Pharm Prax; 1967; 3():70-2. PubMed ID: 5599677
    [No Abstract]   [Full Text] [Related]  

  • 43. The Pharmacy and Therapeutics Committee Part 1: overview.
    Bender FH
    Hosp Formul; 1983 May; 18(5):517-8, 523-4, 533 passim. PubMed ID: 10260199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Challenges of a P & T Committee in a community teaching hospital.
    Cooke DH; Kessler J
    Hosp Formul; 1990 Aug; 25(8):878-82, 886. PubMed ID: 10105706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Promoting rational drug use through the ASHP Commission on Therapeutics.
    Witmer DR
    Am J Hosp Pharm; 1994 Jun; 51(12):1536. PubMed ID: 8092154
    [No Abstract]   [Full Text] [Related]  

  • 46. Developing an effective P & T Committee, Part 2.
    Abramowitz PW; Godwin HN; Latiolais CJ; McDougal TR; Miller WA; Ravin RL
    Hosp Formul; 1985 Oct; 20(10):1071-2, 1078-81, 1086 passim. PubMed ID: 10273830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Purchasing and inventory control--past, present, and future.
    Skolaut MW; McAllister JC
    Am J Hosp Pharm; 1984 Mar; 41(3):522-5. PubMed ID: 6702857
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How Florida's Formulary Committee improved drug purchasing.
    Jones JH; Torosian G
    Hosp Formul; 1977 Apr; 12(4):257-9. PubMed ID: 10305399
    [No Abstract]   [Full Text] [Related]  

  • 49. [Are the drug committees sold?].
    Bystedt T; Gustavsson R
    Lakartidningen; 1993 Oct; 90(41):3518, 3523. PubMed ID: 8231491
    [No Abstract]   [Full Text] [Related]  

  • 50. [Towards a new drug management].
    Hoffmann M; Ahlner J
    Lakartidningen; 1995 Oct; 92(41):3804, 3807. PubMed ID: 7564634
    [No Abstract]   [Full Text] [Related]  

  • 51. [Safer drug handling in hospitals. A new task for the drug committee].
    Osterman PO; Gyllenspetz L; Hartvig P; Levol R; Rane A; Söderström A
    Lakartidningen; 1996 Oct; 93(44):3917-20. PubMed ID: 8965581
    [No Abstract]   [Full Text] [Related]  

  • 52. Implementation of an intravenous potassium policy.
    Cooper BE
    Hosp Pharm; 1989 Jun; 24(6):462-4. PubMed ID: 10293974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Work of the committee on drug side effects].
    Naes K
    Tidsskr Nor Laegeforen; 1975 Aug; 95(22):1237-8. PubMed ID: 1162664
    [No Abstract]   [Full Text] [Related]  

  • 54. Providing health economic data to managed care.
    Navarro RP
    Manag Care Interface; 1998 Sep; 11(9):62-3, 66. PubMed ID: 10187588
    [No Abstract]   [Full Text] [Related]  

  • 55. [Medical experts groups and choice of medications. A fair prioritization process guarantees the reliability of the choice of medications].
    Garpenby P
    Lakartidningen; 2004 Aug; 101(32-33):2480-2, 2484. PubMed ID: 15346621
    [No Abstract]   [Full Text] [Related]  

  • 56. [14. Cooperation between the executive committee C 6 "Dyes in medicine and biology" and dye producers].
    Gerbig KD
    Acta Histochem; 1973; Suppl 13(0):321-6. PubMed ID: 4213583
    [No Abstract]   [Full Text] [Related]  

  • 57. WHO expert committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1984; 704():1-54. PubMed ID: 6437087
    [No Abstract]   [Full Text] [Related]  

  • 58. P & T Committee role in advocating rational therapeutics.
    Borreson R
    Hosp Formul; 1986 May; 21(5):590-8. PubMed ID: 10311625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Registration of adverse effects in drug therapy].
    Skobba TJ
    Tidsskr Nor Laegeforen; 1970 Jan; 90(1):6-9. PubMed ID: 5426192
    [No Abstract]   [Full Text] [Related]  

  • 60. Developing policy for handling investigational drugs.
    Ebel JA
    Hosp Manage; 1967 Aug; 104(2):58-64. PubMed ID: 6073958
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.